- Report
- February 2023
- 240 Pages
Global
From €2901EUR$3,000USD£2,475GBP
- Report
- July 2021
- 60 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- January 2021
- 125 Pages
Global
From €1934EUR$2,000USD£1,650GBP
- Report
- June 2020
- 753 Pages
Global
From €3191EUR$3,300USD£2,722GBP
- Report
- May 2018
- 15 Pages
Global
- Report
- August 2022
- 240 Pages
Global
From €7252EUR$7,500USD£6,187GBP
- Report
- August 2022
- 100 Pages
Global
From €3819EUR$3,950USD£3,259GBP
- Report
- August 2022
- 151 Pages
Global
From €9186EUR$9,500USD£7,837GBP
- Report
- August 2022
- 75 Pages
Global
From €4593EUR$4,750USD£3,919GBP
- Drug Pipelines
- July 2022
- 100 Pages
Global
From €2659EUR$2,750USD£2,269GBP
- Report
- July 2022
- 100 Pages
Global
From €2659EUR$2,750USD£2,269GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,259GBP
- Drug Pipelines
- May 2018
- 70 Pages
Global
From €3384EUR$3,500USD£2,887GBP
- Report
- October 2019
- 117 Pages
Europe
€4593EUR$4,750USD£3,919GBP
- Report
- May 2022
- 159 Pages
Global
From €3384EUR$3,500USD£2,887GBP
- Report
- May 2022
- 43 Pages
Global
From €2417EUR$2,500USD£2,062GBP
- Drug Pipelines
- December 2019
- 112 Pages
Global
From €3384EUR$3,500USD£2,887GBP
- Book
- August 2022
- 320 Pages
- Book
- November 2022
- 300 Pages
KRAS is a family of proteins that are involved in the regulation of cell growth and survival. In oncology, KRAS is a key target for drug development, as mutations in the KRAS gene are associated with a variety of cancers, including colorectal, pancreatic, and lung cancer. KRAS inhibitors are a type of targeted therapy that works by blocking the activity of mutated KRAS proteins, thus preventing cancer cells from growing and spreading.
Currently, there are several companies developing KRAS inhibitors, including Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer. These companies are working to develop drugs that can target specific KRAS mutations, as well as combination therapies that can be used in combination with other treatments. Additionally, there are several clinical trials underway to evaluate the efficacy of KRAS inhibitors in treating various types of cancer. Show Less Read more
